நிர்வி ஆஷர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிர்வி ஆஷர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிர்வி ஆஷர் Today - Breaking & Trending Today

Windlas Biotech IPO: Windlas Biotech offers its shares at 64x PE. Should you subscribe?


NEW DELHI: Analysts tracking primary issues believe one can subscribe to the initial public offering of Windlas Biotech, a Contract Development Manufacturing Organisation (CDMO), for the long term. The issue opens for subscription today.
The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will offload 51,42,067 equity shares worth Rs 236 crore via an offer-for-sale (OFS). The price band for the issue is fixed at Rs 448-460 per share.
“Windlas is focusing on formulation CDMO, and there is no peer company focusing solely on the CDMO model. Considering its return ratios and profitability, the issue seems to be fully priced. But factoring the growth drivers of the CDMO sector and opportunities available for the company, we assign a ‘subscribe for long term’ rating on the issue,” said Rajnath Yadav of Choice Broking. ....

Emcure Pharma , Rajnath Yadav , Nirvi Ashar , Contract Development Manufacturing Organisation , Windlas Biotech , Dehradun Plant , Sanofi India , Cadila Healthcare , Marwadi Shares , Angel Broking , ராஜ்நாத் யாதவ் , நிர்வி ஆஷர் , ஒப்பந்த வளர்ச்சி உற்பத்தி ஆர்கநைஸேஶந் , விண்ட்லாஸ் பயோடெக் , டெஹ்ராடூன் ஆலை , சனோஃபி இந்தியா , காடிலா சுகாதாரம் , மார்வாடி பங்குகள் , தேவதை தரகு ,

Suryoday IPO: Risky bet, aggressively priced: Should you subscribe to Suryoday SFB IPO?


NEW DELHI: The initial public offering (IPO) of Suryoday Small Finance Bank opened for bidding on Wednesday alongside the issue of Nazara Technologies. Analysts seem to have mixed views on the issue, with some pointing to the significant risks that it carries.
The company seeks to raise Rs 581 crore. The primary purpose of the IPO is to meet RBI’s listing requirement within three years of starting banking operations. Unfortunately, it’s being forced to launch its issue amid a pandemic that has left it with more than a few chinks in the armour.
Rajiv Mehta, Lead Analyst for Institutional Equities at Yes Securities, said he does not have a positive view on this IPO for various reasons. He said the company’s asset quality has been impacted severely by Covid-19 and the overall stress remains inadequately addressed. At the same time, its loan-assets diversification is not credible enough, he said. ....

Rajiv Mehta , Nirvi Ashar , Anand Dama , Kiran Vyapar , Ajit Kumar Kabui , Axis Equity Hybrid Fund , Suryoday Small Finance Bank , Axis Flexi Cap Fund , Lead Analyst , Institutional Equities , Yes Securities , Kumar Kabui , Suryoday Ipo , Suryoday Shares , Suryoday Small Finance Bank Ltd , Suryoday Share Price , Suryoday Stock Price , Suryoday Small Finance Bank Ipo , ராஜீவ் மேத்தா , நிர்வி ஆஷர் , ஆனந்த் டமா , கிறன் வியாபார் , அஜித் குமார் கபுய் , அச்சு பங்கு கலப்பு நிதி , சூரியோதாய் சிறிய நிதி வங்கி , அச்சு நெகிழ்வு தொப்பி நிதி ,